Shattuck Labs, Inc.

NasdaqGS STTK

Shattuck Labs, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -1,176.49%

Shattuck Labs, Inc. EBITDA Margin is -1,176.49% for the Trailing 12 Months (TTM) ending September 30, 2024, a 83.53% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Shattuck Labs, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -7,142.99%, a -3,219.01% change year over year.
Shattuck Labs, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -215.21%.
Shattuck Labs, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -270.54%.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NasdaqGS: STTK

Shattuck Labs, Inc.

CEO	Dr. Taylor H. Schreiber M.D., Ph.D.
IPO Date	Oct. 9, 2020
Location	United States
Headquarters	500 West 5th Street
Employees	75
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Key trends

Past 5 years